<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03842982</url>
  </required_header>
  <id_info>
    <org_study_id>CHIPPI-1808</org_study_id>
    <secondary_id>2018-003680-62</secondary_id>
    <nct_id>NCT03842982</nct_id>
  </id_info>
  <brief_title>Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Ovarian Cancer (CHIPPI)</brief_title>
  <acronym>CHIPPI</acronym>
  <official_title>Phase III Randomized Clinical Trial Evaluating Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Ovarian Cancer Considering Two Different Settings: Primary Debulking Surgery (PDS) and Interval Debulking Surgery (IDS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Oscar Lambret</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Oscar Lambret</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase III, multicenter, interventional and randomized study which evaluates the use
      of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) coupled with either Primary Debulking
      Surgery (PDS) or Interval Debulking Surgery (IDS), in patients with ovarian cancer. This
      study aims to assess the efficacy, in terms of disease-free survival (DFS), the use of HIPEC
      combined with standard care (PDS or IDS) or standard care alone.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of this study is to assess the efficacy, in terms of disease-free
      survival (DFS), the use of HIPEC treatment combined with standard care (PDS or IDS) or
      standard care alone (PDS or IDS alone).

      Secondary objectives of the study include:

        -  Evaluating the efficacy of HIPEC in terms of overall survival (OS) in combination with
           standard of care

        -  Evaluating the morbidity associated with HIPEC.

        -  Evaluating the trade-off between efficacy and morbidity using the Q-TWiST approach.

        -  Evaluating the impact of HIPEC in terms of quality of life.

      Exploratory objectives (optional) include:

        -  Evaluating the impact of HIPEC on the count of residual viable cells (evaluated by flow
           cytometry) in abdominal drainage fluids for patients recruited in Centre Oscar Lambret
           only.

        -  Constituting a biobank (tumoral samples and blood samples) for future translational
           researches
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2019</start_date>
  <completion_date type="Anticipated">June 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease-free Survival (DFS)</measure>
    <time_frame>From randomization to first progression, relapse or death from any cause, whichever came first, assessed up to 5 years. (Follow-up up to 5 years)</time_frame>
    <description>The DFS will be measured to assess the efficacy of the combination treatment of surgery and HIPEC or standard care alone.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>From randomization to first progression, relapse or death from any cause , whichever came first, assessed up to 5 years..</time_frame>
    <description>The overall survival will be measured to assess the efficacy of HIPEC in combination with standard care.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events (AE)</measure>
    <time_frame>Covers the whole treatment duration from Randomization up to the end of treatment (surgery or CT) plus 30 days.</time_frame>
    <description>The adverse events (AE) are collected to evaluate the impact of HIPEC on the safety and on the feasibility of adjuvant treatment (if any) is planned after surgery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Q-TWiST</measure>
    <time_frame>Over the 5 year surveillance period</time_frame>
    <description>Q-Twist (Quality-adjusted time without symptoms of disease or toxicity) will be calculated from the survival tile (OS and DFS) and AE (adverse events) data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life of the patient (QLQC30)</measure>
    <time_frame>Up to 2 years after the end of treatment (every 3 month)</time_frame>
    <description>European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Score 30 (QLQ-C30) will be used to measure the quality of life of the patients.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life of the patient (QLQOV28)</measure>
    <time_frame>Up to 2 years after the end of treatment (every 3 month)</time_frame>
    <description>European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Ovarian Cancer Module (QLQ-OV28) will be used to measure the quality of life of the patients.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">432</enrollment>
  <condition>Ovary Neoplasms</condition>
  <condition>Ovarian Cancer</condition>
  <condition>Ovarian Carcinoma</condition>
  <arm_group>
    <arm_group_label>Arm A (PDS or IDS + HIPEC)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Surgery (Primary Debulking Surgery (PDS) or Interval Debulking Surgery (IDS)) + Neo or Adjuvant chemotherapy (standard care) + HIPEC (hyperthermic intraperitoneal chemotherapy)
Patients in this experimental arm will receive surgery (either PDS or IDS) and Neo and/or Adjuvant chemotherapy (CT) (as per standard care) combined with HIPEC. Patients undergoing PDS will also be receiving 6 cycles adjuvant CT according to the standard care (ideally 6 weeks post-surgery).
Patient undergoing IDS will start with 6 cycles of neo-adjuvant CT with a 3 - 5 weeks washout period (4 - 6 weeks if administered Bevacizumab) prior to surgery. They may also undergo additional adjuvant CT post-surgery according to the standard care.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B (PDS or IDS)</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Surgery (Primary Debulking Surgery (PDS) or Interval Debulking Surgery (IDS)) + Neo or Adjuvant chemotherapy ONLY (standard care, without HIPEC)
Patients in the control group will ONLY receive the standard care, which consists of surgery (PDS or IDS) with Neo and/or Adjuvant chemotherapy (CT). Patients undergoing PDS will be receiving 6 cycles adjuvant CT according to the standard care (ideally 6 weeks post-surgery).
Patient undergoing IDS will start with 6 cycles of neo-adjuvant CT with a 3 - 5 weeks washout period (4 - 6 weeks if administered Bevacizumab) prior to surgery. They may also undergo additional adjuvant CT post-surgery according to the standard care.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HIPEC</intervention_name>
    <description>HIPEC protocol (ONLY Arm A) consisted in cisplatin 100mg/m2 intraperitoneally (IP), heated to 40°C for 90 minutes, along with an IV perfusion of sodium thiosulfate.
Administration of the dose should be according the following schedule:
50% of the dose at start of perfusion, 25% of the dose after 30 minutes from start of the perfusion and 25% of the dose after 60 minutes from start of the perfusion.
The procedure takes 120 minutes with a 90-minute perfusion period. The IV perfusion of sodium thiosulfate is for renal protection. At the start of HIPEC procedure, 9 g/m2 in 200 ml of distilled water will be administered by IV over 15 to 30 minutes. It will be then followed by 12 g/m2 in 1 liter (1L) distilled water in a continuous IV for 6 hours.</description>
    <arm_group_label>Arm A (PDS or IDS + HIPEC)</arm_group_label>
    <other_name>Hyperthermic intraperitoneal chemotherapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Pre-eligibility criteria to be checked before surgery for pre-registration

          1. Age ≥18 years and ≤ 76 years

          2. Histologically proven primary epithelial ovarian carcinoma or fallopian tube carcinoma
             or peritoneal carcinoma (including serous papillary adenocarcinoma, clear-cell
             carcinoma, mucinous adenocarcinoma and endometrioid carcinoma)

          3. FIGO (International Federation of Gynecology and Obstetrics) stage III

          4. Patient eligible for

               1. Primary Debulking Surgery (PDS) with planned adjuvant chemotherapy +/-
                  bevacizumab or other targeted therapy

               2. Or Interval Debulking Surgery (IDS) after neo-adjuvant chemotherapy +/-
                  bevacizumab or other targeted therapy, with or without planned adjuvant
                  chemotherapy +/- bevacizumab or other targeted therapy. In case of neo-adjuvant
                  chemotherapy, surgery should be performed in a time interval of 3 to 5 weeks in
                  case of chemotherapy without bevacizumab, and in a time interval of 4 to 6 weeks
                  if chemotherapy is combined with bevacizumab. The patient remains eligible for
                  the study if surgery is delayed beyond the recommended time interval.

          5. WHO (World Health Organization Performance Status) ≤ 2

          6. Physical status score ASA (American Society of Anesthesiologists) ≤ 2

          7. Adequate bone marrow and renal function, as evidenced by the following tests performed
             within 7 days prior to surgery:

               -  Absolute Neutrophil Count (ANC) ≥1,500/mm3

               -  Platelets ≥100,000/mm3

               -  Aspartate aminotransferase (ALT)/ Alanine aminotransferase (ALT) ≤2.5 × upper
                  limit of normal (ULN) (≤5.0 × ULN in case of liver metastases)

               -  Total bilirubin ≤1.5 × ULN (except in case of Gilbert's disease)

               -  Creatinine clearance ≥ 60 mL/ min

          8. Negative serum pregnancy test within 7 days prior to surgery for women of childbearing
             potential. For non-menopausal women, if no hysterectomy is planned, willing to accept
             the use of an effective contraceptive regimen during the treatment period and at least
             6 months after the end of treatment (surgery or adjuvant chemotherapy)

          9. Absence of contraindication to receive the products used in this study (cisplatin and
             products used in neo-adjuvant/ adjuvant chemotherapy) according to the most recent
             SmPC (Summary of Product Characteristics) of these products

         10. Patient is willing and able to comply with the protocol for the duration of the study
             including undergoing treatment and scheduled visits and examinations including
             follow-up

         11. Signed written informed consent

         12. Patient covered by the French or Belgian &quot;Social Security&quot; regime Criteria to be
             checked per-operatively for confirmation of enrolment and randomization

         13. Residual disease after surgery (cytoreduction score CC) CC-0 (no macroscopic residue)
             or CC-1 (residue &lt; 2.5 mm)

         14. Per-operative hemorrhage &lt; 2.5 L

         15. Strictly less than 3 digestive resections performed during surgery

         16. Diuresis during surgery ≥ 1 mL/ kg/ h

        Exclusion Criteria:

          1. Benign disease, borderline disease, non epithelial ovarian carcinoma or carcinosarcoma

          2. Cirrhosis

          3. Known hypersensitivity to any of the study drugs, study drug classes, or excipients in
             the formulation

          4. Auditory impairment

          5. Dehydration or intercurrent disease that contraindicates hyperhydration (including
             cardio-respiratory disease)

          6. Other uncontrolled intercurrent disease including, but not limited to: diabetes;
             hypertension; symptomatic congestive heart or pulmonary failure; renal, hepatic or
             severe gastrointestinal (associated with diarrhea) chronic disease

          7. Any unresolved NCI-CTCAE Grade ≥ 2 toxicity from previous anticancer therapy

          8. Concomitant treatment with prophylactic phenytoin

          9. Receipt of live attenuated vaccine, including yellow fever vaccine, within 30 days
             prior to inclusion (and, if patient is enrolled, up to 30 days after the last
             administration of study treatment)

         10. Pregnant or breastfeeding woman

         11. Psychiatric illness or social situation that would limit compliance with study
             requirement, substantially increase the risk of side effects, or compromise the
             ability of the patient to give written informed consent

         12. Inability to comply with medical follow-up of the trial (geographical, social or
             psychic reasons)

         13. Person under guardianship
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Women with ovarian cancer</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>76 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr Fabrice NARDUCCI, MD</last_name>
    <role>Study Director</role>
    <affiliation>Centre Oscar Lambret, Lille, France</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marie VANSEYMORTIER</last_name>
    <phone>+33 3 20 29 59 18</phone>
    <email>promotion@o-lambret.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Valentine STEEN</last_name>
    <phone>+33 3 20 29 59 18</phone>
    <email>promotion@o-lambret.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre François Baclesse</name>
      <address>
        <city>Caen</city>
        <zip>14076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dr Guillaume BABIN, MD</last_name>
      <email>g.babin@baclessse.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Dr Guillaume BABIN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>DrJean François LE BRUN, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dr Sandrine MARTIN-FRANCOISE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dr Florence JOLY, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dr Emeline MERIAUX, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Jean Perrin</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63011</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dr Christophe POMEL, MD</last_name>
      <email>christophe.pomel@clermont.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Dr Christophe POMEL, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dr Caroline CORNOU, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dr Sophie DUBOIS, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dr Morgane MASSON, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dr Marie-Ange MOURET-REYNIER, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <zip>59020</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr Fabrice NARDUCCI, MD</last_name>
      <email>f-narducci@o-lambret.fr</email>
    </contact>
    <investigator>
      <last_name>Dr Fabrice NARDUCCI, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dr Delphine HUDRY, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dr Eric LEBLANC, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dr Cyril ABDEDDAIM, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dr Annick CHEVALIER-PLACE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ICM-Val d'Aurelle</name>
      <address>
        <city>Montpellier</city>
        <zip>34298</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dr Pierre-Emmanuel COLOMBO, MD</last_name>
      <email>Pierre-Emmanuel.Colombo@icm.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Dr Pierre-Emmanuel COLOMBO, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dr Sébastien CARRERE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dr Anne MOURREGOT, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dr François QUENET, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dr Philippe ROUANET, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dr Olivia SGARBURA, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dr Véronique D'HONDT, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dr Michel FABBRO, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Lyon Sud</name>
      <address>
        <city>Pierre-Bénite</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dr Naoual BAKRIN, MD</last_name>
      <email>naoual.bakrin@chu-lyon.fr</email>
    </contact>
    <contact_backup>
      <last_name>Dr Witold GERTYCH, MD</last_name>
      <email>witold.gertych@chu-lyon.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Dr Naoual BAKRIN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dr Witold GERTYCH, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dr Olivier GLEHEN, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dr Vahan KEPENEKIAN, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dr Benoit YOU, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie de l'Ouest</name>
      <address>
        <city>Saint-Herblain</city>
        <zip>44800</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dr Charlotte BOURGIN, MD</last_name>
      <email>charlotte.bourgin@ico.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Dr Charlotte BOURGIN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dr Jean-Marc CLASSE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dr Cécile LOAEC, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dr Dominique BERTON-RIGAUD, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dr Emmanuelle BOURBOULOUX, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dr Jean-Sébastien FRENEL, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dr Carole GOURMELON, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie de Lorraine</name>
      <address>
        <city>Vandœuvre-lès-Nancy</city>
        <zip>54519</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dr Frédéric MARCHAL, MD</last_name>
      <email>f.marchal@nancy.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Dr Frédéric MARCHAL, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dr Yolanda FERNANDEZ DIEZ, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dr Céline GAVOILLE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dr Marie-Christine KAMINSKY, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dr Sébastien GOUY, MD</last_name>
      <email>sebastien.gouy@gustaveroussy.fr</email>
    </contact>
    <investigator>
      <last_name>Dr Sébastien GOUY, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dr Alexandra LEARY, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>February 13, 2019</study_first_submitted>
  <study_first_submitted_qc>February 14, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 15, 2019</study_first_posted>
  <last_update_submitted>May 13, 2019</last_update_submitted>
  <last_update_submitted_qc>May 13, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 15, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ovarian cancer</keyword>
  <keyword>Hyperthermic intraperitoneal chemotherapy</keyword>
  <keyword>HIPEC</keyword>
  <keyword>Primary Debulking Surgery</keyword>
  <keyword>Interval Debulking Surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
    <mesh_term>Fever</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

